Verve’s second swing at gene editing for heart disease shows early promise

Verve’s second swing at gene editing for heart disease shows early promise

Wall Street analysts said the results for Verve’s therapy appeared competitive on efficacy, while avoiding any major safety concerns — at least so far.

Verve gene-editing therapy lowers cholesterol without serious side effects in early study

Initial Phase 1 data show that a single infusion of Verve-102 led to greater decreases in "bad" LDL cholesterol with higher doses.

VERVE-102 Safely Cuts LDL-C Levels in Early Phase 1b Results

A single infusion of VERVE-102 gene editing therapy achieved dose-dependent lowering in blood PCSK9 and LDL-C in initial results from the Heart-2 trial.

Verve unveils early data from second attempt at heart disease gene editing

Verve Therapeutics is trying to swerve the gene editing industry downturn with new results on a potential one-time treatment to lower cholesterol. The experimental gene editing therapy cut bad cholesterol by levels comparable to approved ...